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Vaccineysis of a series of strains of equine arteritis virus (EAV) of deﬁned virulence for
horses, ranging from the horse-adapted virulent Bucyrus (VB) strain to a fully attenuated vaccine strain derived
from it, identiﬁed 13 amino acid substitutions associatedwith attenuation. These include 4 substitutions in the
replicase proteins and 9 in the structural proteins. Using reverse genetic techniques, these amino acid
substitutions were introduced into a virulent infectious cDNA clone pEAVrVBS derived from the VB strain of
EAV. Inoculation of horses with the recombinant viruses clearly demonstrated that changes in either the
replicase (nsp1, nsp2 and nsp7) or structural proteins (GP2, GP4, GP5 and M) resulted in attenuation of the
virulent VB strain. The recombinant virus with substitutions in the structural proteins was more attenuated
than the recombinant virus with substitutions only in the replicase proteins.
© 2008 Elsevier Inc. All rights reserved.Introduction
Equine arteritis virus (EAV) is an enveloped positive-stranded RNA
virus in the family Arteriviridae, order Nidovirales (Cavanagh, 1997;
Snijder and Meulenberg, 1998). The EAV genome is 12.7 kb and con-
tains 5′ and 3′ untranslated regions (UTR) and nine functional open
reading frames [ORFs; (Snijder and Meulenberg, 1998; Snijder et al.,
1999)]. ORFs 1a and 1b encode two replicase polyproteins (pp1a
and pp1ab) that are post-translationally processed by three ORF1a-
encoded proteinases (nsp1, 2, and 4) to yield at least 13 nonstructural
proteins (nsp 1–12, including nsp7α and 7β) (Snijder andMeulenberg,
1998; van Aken et al., 2006; Ziebuhr et al., 2000). The ORFs 2a, 2b, and
3–7 respectively encode the envelope proteins E, GP2, GP3, GP4, GP5,
and M, and the nucleocapsid protein [N; (Snijder and Spaan, 2006)].
EAV is the causative agent of equine viral arteritis (EVA) and is
widely distributed in equine populations throughout the world
(Huntington et al., 1990; McCollum and Bryans, 1973; Moraillon and
Moraillon,1978). Geographically and temporally distinct strains of EAV
differ in the severity of the clinical disease they induce and in their
abortigenic potential (McCollum and Swerczek, 1978; McCollum et al.,
1999; McCollum et al., 1995; Murphy et al., 1988; Timoney and
McCollum, 1993). While most EAV infections are asymptomatic or
subclinical, some infected horses exhibit clinicalmanifestations of EVAiya).
l rights reserved.(Glaser et al., 1997; Timoney and McCollum, 1993). The consequences
of EAV infection include inﬂuenza-like illness in adult horses, abortion
in pregnant mares, pneumonia and/or enteritis in young foals, and
persistent infection in stallions (McCollum et al., 1999; Timoney and
McCollum, 1993). Although strains of EAV can differ in their virulence,
themolecular determinants of EAV virulence have not been identiﬁed.
EAV was ﬁrst isolated from the lung of an aborted fetus during an
extensive outbreak of respiratory disease and abortion on a Stan-
dardbred breeding farm near Bucyrus, Ohio, in 1953 (Doll et al., 1957a;
Doll et al., 1957b). The virus was identiﬁed prior to the routine
availability of cell culture propagation techniques so it was initially
propagated by serial passage in horses, which markedly enhanced
virulence of the virus. Horsepassage 15of the original (Bucyrus) strain of
EAV (parental virus of prototype ATCC-VR796 strain of EAV, American
TypeCultureCollection) causes severe clinical diseasewith a case fatality
of 50–60% in experimentally inoculated horses (MacLachlan et al., 1996;
McCollum and Timoney, 1999). With the advent of cell culture systems,
the highly virulent (velogenic) Bucyrus (VB) strain of EAV was serially
passaged in cell culture with the aim of developing an attenuated
vaccine for the prevention of EVA. Repeated serial passage of the VB
strain of EAV in primary horse kidney [HK; (McCollum et al., 1961b)],
primary rabbit kidney (RK), and equine dermis (ED; NBL-6; ATCC CCL-
57) cells resulted in attenuation of the virus and to the development of
the modiﬁed live virus (MLV) vaccine (ARVAC®, Fort Dodge Animal
Health) that is in current use in the United States and Canada (Doll et al.,
1968; McCollum, 1969; 1970; McCollum et al., 1961a; McCollum et al.,
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the full spectrum of attenuation of the horse-adapted VB strain of EAV;
speciﬁcally the panel includes viruses at various cell culture passage
levels of theVB strain to the completely attenuated ARVAC® vaccine. The
virulence of these various viruses has already been deﬁnitively
established through experimental infection of horses [Table 1; (Doll et
al., 1957a; Doll et al., 1968; Harry andMcCollum,1981; McCollum,1969;
1981; 1986; McCollum et al., 1961a, 1961b; McKinnon et al., 1986;
Timoney et al., 1988)].
This study was undertaken to determine the molecular basis of
attenuation of the ARVAC® vaccine strain of EAV. Comparative
analyses of the complete genome sequences of four viruses spanning
attenuation of the horse-adapted VB strain to the fully attenuated
ARVAC® vaccine strain were performed and critical amino acid
substitutions likely responsible for virus attenuation were identiﬁed.
Reverse genetic studies utilizing a virulent infectious cDNA clone
derived from the VB strain of EAV (Balasuriya et al., 2007) coupled
with experimental infection of horses were then carried out to
conﬁrm the signiﬁcance of these amino acid substitutions in respect of
attenuation of the virus.
Results and discussion
Comparative sequence analysis of EAV strains with different virulence
phenotypes
To determine the molecular basis of attenuation of the ARVAC®
vaccine strain of EAV, we ﬁrst completed comparative nucleotide and
amino acid sequence analysis of four critical viruses from the panel of
viruses that span the entire spectrum of attenuation of the virulent VB
strain to the ARVAC® vaccine virus (Table 1). The full-length sequences
of three viruses were determined and compared to the published
sequence of the VB virus [GenBank accession number DQ846750;
(Balasuriya et al., 2007)], including one moderately virulent (meso-
genic) (HK-25) and two avirulent (lentogenic) strains of EAV [HK116
and HK131RK111ED24 (ARVAC®; Fort Dodge Animal Health); Table 2].
The genomes of all of the viruses (VB, HK25, HK116, and ARVAC®)were
12,704 nucleotides in length and there were no deletions or insertions
in any of the viruses. The nucleotide sequence of each virus was
translated into individual nonstructural and structural protein amino
acid sequences for comparison.Table 1
Attenuation of the VB strain of EAV by passage in cell culture
Viruses Virulence phenotype/clinical
signs
Reference
VB Strain (H15) Velogenic—fatal disease in adult
horses
MacLachlan et al., 1996;
McCollum and Timoney, 1999
HK25⁎ Mesogenic—less severe disease
(104.8F temp., severe leukopenia)
McCollum et al., 1961b;
McCollum, 1969
HK116⁎ Lentogenic—no clinical signs
and horses developed immunity
to EAV
McCollum et al., 1962;
McCollum, 1969, 1970
HK131RK111ED24⁎
[ARVAC® vaccine]
Lentogenic—no horizontal
transmission. No clinical signs in
inoculated horses. Intramuscular
administration—horses developed
protective immunity
and did not transmit the virus
to contact animals. Intranasal
inoculation—did not immunize
effectively.
Harry and McCollum, 1981;
McKinnon et al., 1986;
Timoney et al., 1988, 2007
H — Passaged in horse, HK — Primary horse kidney cells, RK — Primary rabbit kidney
cells, ED — Equine dermis cells (NBL-6; ATCC CCL-57).
⁎ Each virus is identiﬁed by the cell type followed by the number of passages in that
particular cell type (HK25 and HK116 — EAV VB strain was serially passaged 25 and 116
times respectively in primary horse kidney cells; HK131RK111ED24— EAV VB strainwas
serially passaged in primary horse kidney cells for 131 times, primary rabbit kidney cells
for 111 times, and equine dermis cell line for 24 times).Based on comparison of both the virulence phenotypes and sequence
analysis of the VB, HK25, HK116, and ARVAC® viruses, attenuation of the
VB strain to the mesogenic HK25 virus is associated with two amino
acid changes in the replicase protein (nsp1 Ser141NAsn and Ile156NThr)
and four in the structural proteins (GP4 Leu8NSer; GP5 Asn81NAsp; and
M Ile122NVal, Ala154NThr). The single amino acid change (Asn81NAsp)
in the GP5 protein results in loss of the second glycosylation site in
the GP5 of the HK25 strain. Subsequent cell culture passage in primary
HK cells resulted in further attenuation of the HK25 virus to the lento-
genic HK116 virus that has 7 additional amino acid substitutions, two in
the replicase (nsp2 Arg647NCys and nsp7 Asn1620NThr) and ﬁve in the
structural proteins (GP2 Ile92NThr and Arg223NPro; GP5 Ser100NGly
and Asp104NGly; and M Met81NThr). The HK116 virus is clearly atten-
uated forhorses as compared to theHK25virus (Table 1), conﬁrming that
the amino acid differences between the two viruses are directly related
to further attenuation of the mesogenic HK25 virus to the lentogenic
HK116 virus. To produce the ARVAC® vaccine, the HK116 virus was
further passaged15 times inHKcells, followed respectively by111and24
passages in RK and ED cells. These additional cell culture passages ﬁxed
all of the amino acid substitutions present in the HK116 virus, together
with 40 additional amino acid substitutions as compared to the HK116
virus including 15 in the nonstructural proteins and 25 in the structural
proteins (Table 2). However, the numerous additional amino acid sub-
stitutions that accumulated during further cell culture passage of HK116
to HK131RK111ED24 (ARVAC® seed virus) did not alter the attenuation
phenotype of the virus signiﬁcantly as the virus was already fully
attenuated by HK passage 116 (McCollum, 1969; 1970; McCollum et al.,
1962). Therefore, we consider that the critical amino acid substitutions
responsible for attenuation of the VB strain had occurred by the 116th
passage in primary horse kidney cells (HK116 virus). Although the 40
additional amino acid substitutions that accumulated during cell culture
passage of the HK116 virus to the ARVAC® vaccine virus may also
contribute to further attenuation of the vaccine strain of EAV, it was
impossible to assess their impact given that theHK116 virus alreadywas
fully attenuated for horses.
Comparative nucleotide sequence analysis of the VB, HK25, HK116,
and ARVAC® viruses also identiﬁed 1 nucleotide mutation in the 5′ UTR
(A43NG), 11 silent mutations in the replicase polyproteins (T2775NC,
T2942NA, A6058NG, T7123NC, T8143NC, G8863NA, C8884NT,
C9259NT, C9265NT, G9295NA, and G9526NA), and 5 silent mutations
in the structural proteins (C10090NT, T11247NC,G12360NA, T12399NC,
and C12453NT). The signiﬁcance of these substitutions was not
evaluated further. Interestingly, a single nucleotidemutation at position
10,795 (UNC) abolished the ORF3 stop codon (10,795–10,797
[UAANCAA]) in the ARVAC® vaccine virus and this resulted in a new
stop codon 15 nucleotides downstream (10,810–10,812; UAG). As a
result the GP3 protein of the ARVAC® vaccine virus is 5 amino acids
(163 to 168) longer than that of other sequenced EAV strains.
In summary, a comparisonof thevirulencephenotypes andsequences
of the VB, HK25, and HK116 virus strains identiﬁed 13 amino acid
substitutions that individually or collectivelywouldappear to bedirectly
related to attenuation of theMLV vaccine (ARVAC®) strain of EAV. These
include 4 amino acid substitutions in the replicase proteins (nsp1:
Ser141NAsn, Ile156NThr; nsp2: Arg647NCys; and nsp7: Asn1620NThr)
and 9 amino acid substitutions in the structural proteins (GP2:
Ile92NThr, Arg223NPro;GP4: Leu8NSer;GP5:Asn81NAsp, Ser100NGly,
Asp104NGly; and M: Met81NThr, Ile122NVal, Ala154NThr) of EAV
(Table 2).
Generation and in vitro characterization of chimeric and site-directed
mutant viruses
Unequivocal determination of the signiﬁcance of individual amino
acid substitutions is best achieved using a reverse genetics approach.
Therefore, to clarify the contribution of the 4 amino acid substitutions
in the replicase polyproteins (nsp1, nsp2 and nsp7) and 9 substitutions
Table 2
Comparative amino acid analysis of EAV strains with different virulence phenotypes
ORF Protein (aa length) Amino acid difference
Position VBS HK25 HK116 ARVAC
ORF1ab (225–9751) Nonstructural proteins
nsp1: Met1–Gly260 (260) 9 Phe Leu Phe/Leu⁎ Phe
51 Val Met Met Val
141 Ser Asn Asn Asn
145 Ala Ala Ala Val
156 Ile Thr Thr Thr
nsp2: Gly261–Gly831 (571) 388 Thr Thr Thr Ile
402 Arg Arg Arg His
404 Ser Ser Ser Cys
500 Leu Leu Leu His
525 Val Val Val Met
579 Gln Gln Gln His
647 Arg Arg Cys Cys
nsp3: Gly832–Glu1064 (233) 873 Thr Thr Thr Ile
957 Ala Thr Ala Ala
nsp4: Gly1065–Glu1268 (204) –† – – – –
nsp5: Ser1269–Glu1430 (162) 1372 Met Met Met Leu
nsp6: Gly1431–Glu1452 (22) – – – – –
nsp7: Ser1453–Glu1677 (225) 1486 Ala Val Ala Ala
1620 Asn Asn Thr Thr
nsp8/9: Gly1678–Asn1727(50)/Glu2370(693) 1970 Asp Gly Gly Gly
2028 Lys Lys Lys Arg
nsp10: Ser2371–Gln2837 (467) 2449 Ile Ile Ile Val
nsp11: Ser2838–Glu3056 (219) 2948 Ala Ala Ala Val
2992 Asp Asp Asp Gly
nsp12: Gly3057–Val3175 (119) – – – – –
Structural proteins
ORF2a (9751–9954) E (67) – – – – –
ORF2b (9824–10,507) GP2 (227) 62 Tyr Tyr Tyr His
92 Ile Ile Thr Thr
158 Gly Gly Gly Glu
223 Arg Arg Pro Pro
ORF3 (10,306–10,797)§ GP3 (163) 80 Leu Leu Leu Val
123 Leu Leu Leu Ser
160 Cys Cys Cys Tyr
164 Stop Stop Stop Gln
165 Phe
166 Tyr
167 Leu
168 His
169 Stop
ORF4 (10,700–11,158) GP4 (152) 4 Tyr Tyr Tyr Ser
8 Leu Ser Ser Ser
29 Ala Ala Ala Thr
37 Ile Ile Ile Thr
ORF5 (11,146–11,913) GP5 (255) 69 Leu Leu Leu Pro
72 Gln Gln Gln Lys
81 Asn Asp Asp Asp
100 Ser Ser Gly Gly
104 Asp Asp Gly Gly
106 Met Met Met Val
170 Ala Ala Ala Ser
214 Gly Gly Gly Glu
ORF6 (11,901–12,389) M (162) 38 Leu Leu Leu Ser
49 Phe Phe Phe Leu
71 Val Val Val Ala
81 Met Met Thr Thr
122 Ile Val Val Val
150 Phe Phe Phe Cys
154 Ala Thr Thr Met
ORF7 (12,313–12,645) N (110) 13 Phe Phe Phe Val
17 Arg Arg Arg Trp
104 Val Val Val Ile
Total no. aa substitutions compared to the VB strain 0 11 16 52
Note: ⁎ Phe/Leu: Phe or Leu; –†: no amino acid changes occurred. Critical amino acid substitutions are indicated in bold; § In the case of ARVAC®, the ORF3 is nucleotides 10,306–
10,812 and the GP3 is 168 amino acids in length.
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these substitutions were introduced into a virulent infectious
cDNA clone (pEAVrVBS) that was derived from the VB strain of EAV[DQ846751; (Balasuriya et al., 2007)]. The 4 amino acid substitu-
tions in the replicase were introduced into the pEAVrVBS clone using
site-speciﬁc mutagenesis to produce a recombinant virus identiﬁed
Fig. 1. Growth properties of rVBS, rVBS/HK116S and rVBS/VaccNS4m viruses in equine endothelial cells (EECs). Subconﬂuent EECs were inoculated with each of the rVBS, rVBS/
HK116S, and rVBS/VaccNS4m viruses (P0) at a multiplicity of infection of 5. At 0, 6, 12, 24, 48, and 72 h post-infection, supernatants were harvested and virus titers were determined
by plaque assay in RK-13 cells as previously described (McCollum et al., 1962).
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contained in the structural proteins of the HK116 virus (Table 2), the
genes (ORFs 2a-7) encoding all of the structural proteins in the
pEAVrVBS clone were entirely replaced by the same genes from
the HK116 virus to produce the rVBS/HK116S virus. While the rVBS/
HK116S and rVBS viruses had similar growth kinetics in equine
endothelial cells (EECs), infection with the rVBS/HK116S virus yielded
somewhat lower virus titers (∼1 log10 lower in virus yield) than either
the rVBS or rVBS/VaccNS4m viruses (Fig. 1). However, all three viruses
produce identical large plaques in EECs (data not shown), which is
consistent with our previous ﬁnding that both the VB andMLV vaccine
strains of EAV produce large plaques in EECs (Moore et al., 2003).
Virulence phenotypes of chimeric and site-directed mutant viruses in
horses
The virulence phenotypes of the rVBS/HK116S and rVBS/VaccNS4m
viruses were determined by experimental infection of horses. Each
virus was inoculated intranasally into four horses that then were
monitored for the development of clinical signs of EVA (Table 3). Mean
rectal temperature signiﬁcantly increased by 6–7 days post-infection
(DPI) in horses infected with the rVBS/VaccNS4m virus compared to
horses infected with the rVBS/HK116S virus (Pb0.05, Fig. 2A). Horses
inoculated with rVBS/HK116S only developed mild serous nasal
discharge (three of the four horses for three days) whereas some of
the horses inoculated with rVBS/VaccNS4m developed typical clinical
signs of EVA, conﬁrming that this virus is less attenuated than rVBS/Table 3
Comparison of clinical signs caused by infection with three EAV strains
Clinical signs rVBS virusa,b
Rectal temperature Fever (38.9–40.6 °C) in 4 horses for 5–6 days
Edema Moderate to severe limb edema in 4 horses for 4–6 days
Nasal discharge Serous nasal discharge in 4 horses for 1–9 days
Conjunctivitis Mild conjunctivitis in 4 horses for 1–5 days
Hemorrhage Petechial and ecchymotic hemorrhages in the oral
mucous membranes of 4 horses for 2–5 days
Urticarial-type rash (hives) Urticarial-type rash (hives) on the neck, shoulder
and along the back of 2 horses for 2–3 days
a Each virus was inoculated into 4 horses.
b Balasuriya et al., 2007.HK116S. Lymphopenia occurred in all horses infected with either the
rVBS/HK116S or rVBS/VaccNS4m viruses. However, the severity varied
markedly between individuals and there was no signiﬁcant difference
between horses infectedwith the two viruses through 14 DPI (Fig. 2B).
Virus was isolated from the nasal secretions (NS) and peripheral
blood mononuclear cells (PBMCs) collected from all horses inoculated
with the rVBS/HK116S and rVBS/VaccNS4mviruses, with minimal titers
of virus in plasma (b101 pfu/ml). Virus was isolated from the NS of all of
the horses inoculatedwith either virus strain from 2 through 10–12 DPI,
with the peak titer on 6 DPI (Fig. 3A). The rVBS/HK116S-inoculated
horses shed lower concentrations of virus in NS than the rVBS/
VaccNS4m-inoculated horses between 8–10 DPI (Pb0.02, Fig. 3A). As
compared to the rVBS/VaccNS4m-inoculated horses, onset of viremia
was delayed in the rVBS/HK116S-inoculated horses (Fig. 3B). Similarly,
duration of viremia was shorter in the rVBS/HK116S-inoculated horses
compared to the rVBS/VaccNS4m-inoculated horses (Fig. 3B). Also, the
virus titer in PBMCs of rVBS/HK116S-inoculated horses was signiﬁcantly
lower than that detected in the rVBS/VaccNS4m-inoculated horses on
2–6 DPI and 12–14 DPI (Pb0.005, Fig. 3B). All of the horses inoculated
with the rVBS/VaccNS4m and rVBS/HK116S viruses seroconverted by
8 DPI, with serum neutralizing antibody titers increasing to 256–512
by 14DPI (Fig. 4). Viruses recovered from theNS on 6DPI and the PBMCs
on 8 DPI from two of the rVBS/HK116S-inoculated horses and two of the
rVBS/VaccNS4m-inoculated horses were RT-PCR ampliﬁed and
sequenced. The sequences of the viruses recovered from the horses
were identical to those of the respective viruses that were used to
inoculate each group of horses, conﬁrming stability of the input virusesrVBS/VaccNS4m virusa rVBS/HK116S virusa
Fever (39–39.6 °C) in 2 horses for 2–3 days Fever (39.4 °C) in 1 horse for 2 days
Moderate to severe limb edema in 3 horses
for 11–12 days
No limb edema in any horse
None of the horses had a nasal discharge Mild serous nasal discharge in 3 horses
for 3 days
Mild conjunctivitis in 1 horse for 4 days No conjunctivitis in any horse
Petechial hemorrhages in the oral mucous
membranes of 2 horses for 1 day
None of the horses developed mucosal
hemorrhages
No hives in any horse No hives in any horse
Fig. 2. Rectal temperature (A) and peripheral blood lymphocyte counts (B) of horses inoculated with rVBS, rVBS/HK116S and rVBS/VaccNS4m viruses. Four horses were inoculated
with each virus. The mean and standard deviation of temperature and cell counts are shown.
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that these two viruses having amino acid substitutions in either the
replicase or structural proteins are attenuated and, furthermore, that
rVBS/HK116S is more attenuated than the rVBS/VaccNS4m virus.
Since both recombinant viruses have the backbone of the virulent
pEAVrVBS infectious cDNAcloneof EAV, the virulence phenotypes of the
rVBS/HK116S and rVBS/VaccNS4mviruseswere also compared to that of
theparental rVBSviruswhichproduces severedisease in experimentally
inoculated horses [Table 3; (Balasuriya et al., 2007)]. The average rectal
temperature of the rVBS-inoculated horseswas signiﬁcantly higher than
thatof the rVBS/HK116S and rVBS/VaccNS4mvirus-inoculatedhorses by
2–7DPI (Pb0.02, Fig. 2A). Nasal virus shedding and viremiawere similar
between rVBS- and rVBS/VaccNS4m-inoculated horses (Figs. 3A and B),
whereas both nasal shedding of virus and viremia in rVBS/HK116S-
inoculated horses were signiﬁcantly lower than that in rVBS- and rVBS/
VaccNS4m-inoculated horses (Pb0.05 for nasal virus shedding on
8–10 DPI; Pb0.03 for virus titer in PBMCs on 2–6 DPI and 12–14 DPI;
Figs. 3A and B). The rVBS, rVBS/VaccNS4m and rVBS/HK116S viruses all
caused moderate lymphopenia in inoculated horses. Lymphopenia
caused by rVBS virus infection was more severe than that caused by
rVBS/HK116S on only 2 and 4 DPI (Pb0.03) (Fig. 2B). It has been
previously shown that horses vaccinated with the ARVAC® vaccine and
horses inoculated with avirulent ﬁeld strains of EAV also can develop
transient lymphopenia (Harry and McCollum, 1981; McCollum, 1981;
McKinnon et al., 1986; Patton et al., 1999; Timoney et al., 2007; Timoney
andMcCollum,1993). In summary, the rVBS/HK116S virus hadmarkedlyreducedvirulence forhorses as compared to theparental rVBS strain and
the rVBS/VaccNS4m strain and caused only subclinical infection. The
rVBS/VaccNS4mvirus causedmilder clinical disease as compared to the
parental rVBS strain.
Amino acid substitutions in either the nonstructural or structural proteins
of EAV can cause attenuation
The availability of a panel of proven virulent and attenuated EAV
strains derived from a common ancestor provides a unique resource
to characterize the molecular basis of attenuation of the MLV EAV
vaccine. In this study, four EAV strains with deﬁned virulence
phenotypes were selected from a panel of viruses that span the
entire spectrum of attenuation of the VB strain, and these viruses
were used to identify the viral determinants of attenuation. Com-
parative sequence analysis showed that attenuation of the velogenic
VB strain to the mesogenic (HK25) strain was associated with two
amino acid substitutions in the replicase protein (nsp1) and four in the
structural proteins (GP4, GP5 and M). Subsequent passage of the
mesogenic HK25 virus led to further attenuation to the lentogenic
HK116 virus through acquisition of two additional amino acid
substitutions in the replicase proteins (nsp2 and nsp7) and ﬁve in
the structural proteins (GP2, GP5 and M). Additional amino acid
mutations occurred during further cell culture passage of the HK116
virus to the ARVAC® vaccine; however, these additional mutations do
not appear to be critical to virus attenuation because the HK116 virus
Fig. 4. Serum-neutralizing antibody responses in horses inoculated with rVBS, rVBS/HK116S and rVBS/VaccNS4mviruses. Four horses were inoculated with each virus. The mean and
standard deviation of reciprocal antibody titers are shown.
Fig. 3. Virus isolation from nasal secretions (A) and peripheral blood mononuclear cells (B) of horses inoculated with rVBS/HK116S and rVBS/VaccNS4m viruses. Four horses were
inoculated with each virus. The mean and standard deviation of virus titers are shown.
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361J. Zhang et al. / Virology 378 (2008) 355–362was already fully attenuated for horses (McCollum, 1969; 1970;
McCollum et al., 1962).
To further characterize the amino acid substitutions responsible
for the attenuation phenotype of the ARVAC® vaccine, two recombi-
nant viruses were produced using the virulent EAV infectious cDNA
clone pEAVrVBS as the backbone. Experimental inoculation of horses
with these two recombinant viruses clearly demonstrated that amino
acid changes in either the replicase (nsp1, nsp2 and nsp7) or structural
proteins (GP2, GP4, GP5 and M) resulted in attenuation. However, the
recombinant virus with multiple substitutions in the structural
proteins was more attenuated than the recombinant virus with sub-
stitutions only in the replicase proteins. The signiﬁcance of the
numerous silent mutations that occurred during cell culture passage
of the VB strain was not directly evaluated by reverse genetic studies,
but attenuation of the chimeric viruses occurred without any
mutation of the 5′ UTR. Similarly, it was recently shown that sub-
stitutions in both the structural and nonstructural proteins of the
related porcine reproductive and respiratory syndrome virus also lead
to its attenuation (Wang et al., 2008). In summary, it appears that
attenuation of arteriviruses is a complex process that maywell involve
a variety of structural and nonstructural viral proteins, and perhaps
the interaction of different proteins.
A variety of human and animal MLV vaccines have been produced
by extensive serial cell culture passage of virulent viruses, a process
that likely selects for speciﬁc virus clones of altered virulence pheno-
type that already are present in the quasispecies population and
which grow preferentially in cell culture (Flint et al., 2004). Attenua-
tion often involves considerably more than single nucleotide/amino
acid changes in individual virus genes. For example, the three sero-
types included in the Sabin oral poliovirus vaccine have substitutions
in both the 5′-UTR and structural protein genes [P1/Sabin — 5′-UTR,
VP1, VP3 and VP4; P2/Sabin— 5′-UTR and VP1; and P3/Sabin— 5′-UTR
and VP3; (Flint et al., 2004)]. Similarly, attenuation of the TC-83 MLV
vaccine strain of Venezuelan equine encephalomyelitis virus has been
mapped to a single nucleotide substitution in the 5′-UTR and mul-
tiple amino acid substitutions in E1 and E4 envelope glycoproteins
(Davis et al., 1991; Johnson et al., 1986; Johnston and Smith, 1988;
Kinneyet al.,1993;White et al., 2001). Recently, attenuation of theNew
York 99 strain of West Nile virus was mapped to multiple amino acid
substitutions in the nonstructural (NS2A, NS3, NS4B and NS5) and E
proteins, including loss of a glycosylation site (Beasley et al., 2004;
Beasley et al., 2005; Davis et al., 2004; Wicker et al., 2006). The data
from the current study also indicate that attenuation of the MLV
vaccine (ARVAC®) strain of EAV is the result of an accumulation of point
mutations at multiple independent loci in the genes encoding the
envelope and nonstructural proteins of the virus. Furthermore, it is
very likely that there are additional loci responsible for the virulence
and attenuation of ﬁeld strains EAV that would not be identiﬁed under
the condition of this study.
Materials and methods
Viruses and cells
Four EAV strains of common ancestry but with deﬁned dif-
ferent virulence phenotypes [VB strain (horse passage 15; H15),
HK25, HK116 and HK131RK111ED24 (ARVAC®, Fort Dodge Animal
Health)] were included in this study (Table 1). Tissue culture ﬂuid
(TCF) supernatants containing rVBS was stored at −80 °C from a
previous study (Balasuriya et al., 2007). Equine pulmonary artery
endothelial cells (EECs) were grown in Dulbecco's modiﬁed essen-
tial medium with sodium pyruvate, 10% fetal bovine serum, anti-
biotics, and 200 mM L-glutamine (Hedges et al., 2001; Moore et al.,
2002). The rabbit kidney cells (RK-13, ATCC CCL-37) were grown in
Eagle's minimum essential medium with 10% ferritin supplemented
bovine calf serum and antibiotics.Isolation of viral RNA, RT-PCR ampliﬁcation and sequencing
Viral RNA was isolated from the TCF of the HK25, HK116, and
HK131RK111ED24 (ARVAC®) strainsusing theQIAampviral RNAmini kit
(Qiagen). The full-length genomes of these three viruses were RT-PCR
ampliﬁed in ﬁve overlapping fragments [nucleotide (nt) 1–2482;
nt 2169–5217; nt 4718–7850; nt 7391–10,148; and nt 9570–12,704]
using the Superscript III (Invitrogen) and the high-ﬁdelity proof-reading
PfuTurbo DNA polymerase (Stratagene). The PCR products were gel-
puriﬁedusingQIAquick gel extraction kit (QIAGEN). Both sense and anti-
sense strands were sequenced using an ABI 377 Automatic sequencer
(Applied Biosystems). Sequence data were analyzed using CodonCode
Aligner v1.5.2 (CodonCode) and Vector NTI Advance 10 (Invitrogen).
Generation of chimeric and site-directed mutant viruses
Thechimeric infectious cDNAclonepEAVrVBS/HK116Swasconstructed
by substituting the structural protein genes (ORFs 2a-7) of the infectious
cDNA clone pEAVrVBS which was derived from the VB strain of EAV
(Balasuriya et al., 2007) with the corresponding structural protein genes of
the HK116 virus. The recombinant infectious cDNA clone pEAVrVBS/
VaccNS4m was constructed by introducing four site-speciﬁc nucleotide
changes that were present in attenuated viruses HK116 and ARVAC® into
thepEAVrVBSclone [nsp1ntG646>A(Ser141>Asn), T691>C(Ile156>Thr),
nsp2 C2163>T (Arg647>Cys), and nsp7 A5083>C (Asn1620>Thr)] using
QuikChange Multi Site-directed Mutagenesis Kit (Stratagene). Viral RNA
transcripts were in vitro-transcribed from the XhoI-linearized full-length
infectious cDNA clones pEAVrVBS/HK116S and pEAVrVBS/VaccNS4m and
RNA transcripts were transfected into EECs by means of electroporation
following previously described protocols (Balasuriya et al., 1999) to
generate the recombinant viruses rVBS/HK116S and rVBS/VaccNS4m.
Viruses (Passage 0 [P0]) harvested from transfected EECs were used for in
vitro and in vivo studies. The authenticity of these recombinant viruses [P0]
was conﬁrmed by sequencing as described above.
Growth characteristics of recombinant viruses in EEC cells
Monolayers of EECs grown in6-well plateswere inoculatedwith each
of the rVBS, rVBS/HK116S, and rVBS/VaccNS4m viruses at a multiplicity
of infection of 5 and held at 37 °C for 1 h. The inocula were aspirated off
and the cell sheets washed three times with phosphate buffered saline
(PBS, pH7.4) to removeunboundvirus, then overlaidwith 4mlof culture
medium. This was designated time zerowith respect to infection. At 0, 6,
12, 24, 48, and 72 h post-infection, supernatants were harvested and
virus titers were determined by plaque assay in RK-13 cells as previously
described (McCollum et al., 1962).
Experimental infection of horses with recombinant viruses
Eight EAV seronegative Thoroughbred horses (age 6–14 years old)
were randomly assigned to two groups. Group one (n=4) and group two
(n=4) were inoculated intranasally with the rVBS/HK116S virus and
rVBS/VaccNS4m virus, respectively, using a fenestrated catheter. Each
horsewas inoculated intranasallywith 1.0×107pfuof each virus in 5.0ml
of culture medium. Horses were observed for the appearance of clinical
manifestations of EVA twice daily over theﬁrst twoweeks after infection
and once daily for an additional two weeks. Blood samples were
collected at 0, 2, 4, 6, 8, 10, 12, and 14 DPI for complete blood cell counts.
Blood samples were also collected for separation of peripheral blood
mononuclear cells (PBMCs) for virus isolation at 0, 2, 4, 6, 8,10,12,14, 21,
28, 35, 42, 49, 56, and 63 DPI. Nasopharyngeal swabswere collected at 0,
2, 4, 6, 8, 10, 12, 14, 21 and 28 DPI. Virus isolation from PBMCs and nasal
swabs was attempted in RK-13 cells as described previously (Balasuriya
et al., 1999). The serum neutralizing antibody response to EAV was
determined in each horse at 0, 2, 4, 6, 8, 10, 12, 14, 21, 28, 35, and 42 DPI
following previously described protocols (Senne et al., 1985).
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The nucleotide sequences of the HK25, HK116, and ARVAC viruses
were deposited in GenBank under the accession numbers EU586273,
EU586274 and EU586275, respectively.
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